Wednesday, February 26, 2020 Daily Archives

Sandoz optimistic on biosimilars as it reprioritizes US portfolio

by

Sandoz US president Carol Lynch talks about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo. Sandoz International GMBH is shrinking the size of its US footprint as it prioritizes complex generics and biosimilars in the region and divests much of its small molecule generics portfolio to India’s Aurobindo Pharma Ltd. US President Carol Lynch talked about the changing dynamics for the US business and the company’s…

February 26, 2020

Iovance on balancing $85m inhouse plant with CDMO WuXi

by

Iovance will use CDMO WuXi Apptec for initial commercial supply of lifileucel, but a Philadelphia plant under-construction looks to bring its tumor infiltrating lymphocyte (TIL) cell therapies inhouse. Iovance announced in June last year that it is constructing a 136,000 square-foot facility in Philadelphia, Pennsylvania to manufacture its pipeline of autologous cell therapy candidates. At the time, the plant was expected to cost Iovance $75 million (€69 million) over three years “for equipment and construction of the manufacturing suites,†but…

February 26, 2020

Fujifilm breaks ground at $54m NC biologics plant expansion

by

The expansion at a cell culture facility in Research Triangle Park will feed the demand for growing biologics pipelines, says CDMO Fujifilm Diosynth Biotechnologies. Contract development and manufacturing organization (CDMO) Fujifilm broke ground on a 31,778 square-foot extension at its site in Research Triangle Park, Morrisville, North Carolina, which will add recovery and purification suites to support biomanufacturing. The firm says it will increase its cell culture manufacturing capacity by approximately 25% and microbial capacity by approximately 50% when the…

February 26, 2020